Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
about
Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancerPhosphorylation-mediated regulation of GEFs for RhoAApproaches of targeting Rho GTPases in cancer drug discoveryRho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and diseaseStructural and Energetic Mechanisms of Cooperative Autoinhibition and Activation of Vav1MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer.Vav3 oncogene is upregulated and a poor prognostic factor in breast cancer patientsLigand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancerSecretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancerVav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.A kernel-based integration of genome-wide data for clinical decision support.The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasisBypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation.Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characterization.A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancerGenome-wide association study of susceptibility loci for breast cancer in Sardinian population.Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.Hemostatic gelatin sponge is a superior matrix to matrigel for establishment of LNCaP human prostate cancer in nude miceIntegrated network model provides new insights into castration-resistant prostate cancerVav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survivalNovel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.Androgen receptor signaling in prostate cancer.RhoC and guanine nucleotide exchange factor Net1 in androgen-unresponsive mouse mammary carcinoma SC-4 cells and human prostate cancer after short-term endocrine therapy.Genes and molecular pathways related to radioresistance of oral squamous cell carcinoma cells.Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway.Inhibition of gastric cancer cell growth and invasion through siRNA-mediated knockdown of guanine nucleotide exchange factor Vav3.Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.Microarray analysis and biochemical correlations of oxidative stress responsive genes in retinoblastoma.Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancerPreferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide.Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells.Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
P2860
Q26782144-5F8AFFA0-7C96-49DC-9B5D-3373B9E2244EQ26823650-9B2812B1-F7E1-42DB-842C-1D0F812FDD31Q26851300-394ED622-1BD8-47A0-B5A7-354DEBCEC18DQ26853181-2FDE981C-67E7-4C5F-8777-682D3E070070Q27659655-6A16B9DE-E8C1-4037-9B9B-3348AC85FEE6Q30009013-2683D902-D8CD-4410-B41E-0D5186E5F117Q30384535-557B063D-949C-4F76-B2C7-024E1C707308Q30440162-B39B131A-0C7B-4390-AD6B-3BC016A4D28EQ30497364-04B94595-912A-46F0-A3D6-1673E3C593C3Q33339736-546B3301-24DC-4A04-9806-D608A96A0D1AQ33428301-B80864EF-697A-4EF4-9037-76D5435F16CBQ33518516-A547E1FA-A3C1-4D33-94DD-B96AAA296317Q33728239-997FE929-4B60-4AB9-83CD-A2A6526D1E4BQ33944881-8D3527B1-7DE2-400F-8FC8-C68A8592EB95Q34094060-AAB039C7-D0C9-4734-9ECD-958DACA3D7A3Q35198158-20CAD737-C978-46E5-919B-41BCE08028A3Q35465076-B9068298-5E9C-4415-A98F-91428BDBD971Q35615396-3378ACA0-4DEA-4405-8AE5-83D416E1551DQ35650240-90161E2F-617E-4AA7-885E-B6BBF0E5D12BQ36243387-188733C8-3E14-44EF-AD82-0DAAE64A6728Q36316657-675D7F12-977A-4F68-9EB6-549428C60378Q36454548-C452FF70-5BA7-45EA-B079-D1BEAD6861E0Q36635865-BF218E93-2208-40CC-8F7C-AF43DFB6BF4CQ37315118-45C2F24C-3DBE-4BA1-9F8A-E9DE04D965B9Q38175320-EAE83C99-6392-469E-BB38-FA823CF9C0DAQ38330186-8E8241EE-6E32-4907-A5BD-5CAC6D2B97DDQ38516742-A67681E4-257D-4BFB-882B-99996EE42235Q38552283-7A32483F-E544-4B83-9FBA-28FFB107BC84Q38937276-CBFB19F5-52C3-44E5-97EA-A6AC53AC9ED9Q39090736-A18FB969-6CA6-49E1-94EF-35EC294AB905Q39169561-5E1F910E-D7E3-42F5-8059-DCB19663F8E6Q39336736-C69719E5-249D-4C2E-9AF0-53B1738509A4Q39435549-BDE998D7-32C3-4325-B822-81967D454E49Q39673124-7610A6A9-0B82-43A2-9E50-D3D563B8F26DQ39757062-89812005-9DEC-4666-A99C-7DD31D1BE696Q52683959-E2A2B2A0-8AC4-46B8-89FE-0AB1C208A1F0
P2860
Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@ast
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@en
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@nl
type
label
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@ast
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@en
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@nl
prefLabel
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@ast
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@en
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@nl
P2093
P356
P1476
Vav3 oncogene is overexpressed ...... vity in human prostate cancer.
@en
P2093
Lu-Hai Wang
Monica Revelo
Zhongyun Dong
P304
P356
10.1210/ME.2006-0048
P577
2006-06-08T00:00:00Z